Abstract
Several cationic amphiphilic drugs cause local or systemic phospholipidosis (PLD) after chronic exposure in preclinical species. PLD is characterized by the accumulation of drug, phospholipid, and concentric lamellar bodies in cellular lysosomes. We have developed a fluorescence-based in vitro screen that is predictive of PLD using the Cellomics ArrayScan high-content screening platform, which captures and analyzes images from 96-well cell culture microtiter plates using multichannel fluorescence microscopy. I-13.35 adherent mouse spleen macrophage cells were cultured with drug and a fluorescently tagged phospholipid, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE). Drug concentrations were used in a range from 1 to $100 μmol/L. After 24 h incubations, the cells were fixed with formalin. NBD-PE uptake was quantified in controls and treated cells. Nuclei were identified by Hoechst 33258 staining and dead cells were identified using ethidium homodimer-2 incorporation. Thus, confounding accumulation of NBD-PE due to cytotoxicity that produces false-positive results at high concentrations was eliminated from quantitation by ethidium staining and employing cell gating (dead cell rejection). The assay was found to be both sensitive and selective in that 26 of 28 positive, phospholipidogenic controls and 8 of 8 negative, nonphospholipidogenic controls were correctly called.
Similar content being viewed by others
Abbreviations
- CADs:
-
cationic amphiphilic drugs
- DMSO:
-
dimethyl sulfoxide
- EthD-2e:
-
ethidium homodimer-2 dead cell stain
- HCB:
-
high-content biology
- NBD-PE:
-
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-hexadecanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt
- PLD:
-
phospholipidosis
References
Bockhardt H, Lullmann-Rauch R. Zimelidine-induced lipidosis in rates. Acta Pharmacol Toxicol (Copenh). 1980;47(1):45–8.
Casartelli A, Bonato M, Cristofori P, et al. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol Toxicol. 2003;19:161–76.
Cox JW, Ulrich RG, Wynalda MA, et al. Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate. Biochem Pharmacol. 1989;38(20): 3535–41.
Cramer CT, Ulrich RC. Cytotoxicity and lamellar body induction potential of a racemic benzamide antiarrhythmic compound and enantiomers in cultured rat hepatcotyes. Toxicol In Vitro. 1994;5:1083–90.
Dake MD, Madison JM, Montgomery CK, et al. Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity. Am J Med. 1985;78:506–12.
Drenckhahn D, Kleine L, Lullmann-Rauch R. Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab Invest. 1976;35(2):116–23.
Drew R, Siddik ZH, Mimnaugh EG, Gram TE. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab Dispos. 1981;9:322–6.
Frisch W, Lullmann-Rauch R. Differential effects of chloroquine and of several other amphiphilic cationic drugs upon rat choroid plexus. Acta Neuropathol (Berl). 1979;46(3):203–8.
Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac) induced pulmonary disease. Chest. 1995;107:1763–5.
Gum R, Hickman D, Fagerland JA, et al. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem Pharmacol. 2001;62:1661–73.
Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997;25:53–60.
Hollemans M, Elferink RO, DeGroot PG, Strijland A, Tager JM. Accumulation of weak bases in relation to intralysosomal pH in cultured human skin fibroblasts. Biochim Biophys Acta. 1981;643:140–51.
Honegger UE, Roscher AA, Wiesmann UN. Evidence for lysosomotropic action of desipramine in cultured human fibroblasts. J Pharmacol Exp Ther. 1983;225(2):436–41.
Horn JW, Jensen CB, White SL, et al. In vitro and in vivo ultrastructural changes induced by macrolide antibiotic LY281389. Fundam Appl Toxicol. 1996;32:205–16.
Hostetler KY, Richman DD. Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. Biochem Pharmacol. 1982;31(23):3795–9.
Hostetler KY, Reasort M, Yazaki PJ. Chloroquine-induced phospholipid fatty liver: measurements of drug and lipid concentrations in rat liver lysosomes. J Biol Chem. 1985;260:215–9.
Hostetler KY, Giordano JR, Jellison EJ. In vitro inhibition of lysosomal phospholipase A of rat lung by amiodarone and desethylamiodarone. Biochim Biophys Acta. 1988;959:316–21.
Joshi UM, Rao P, Kodacanit S, Coudert B, Dwyer TM, Mehendale HM. Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther. 1988;246:150–7.
Joshi UM, Kodavanti PRS, Lockard VG, Mehendale HM. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim Biophys Acta. 1989;1004:309–20.
Jung HJ, Suzuki Morphological changes in CNS of rats treated with perhexiline maleate (pexid). Acta Neuropathol (Berl). 1978;42(3):159–64.
Kacew S, Reasor MJ. Newborn response to cationic amphiphilic drugs. Federation Proceedings. 1985;44(7):2323–7.
Kacew S. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. Toxicol Appl Pharmacol. 1987;91(3):469–76.
Kannan R, Sarma J, Guha M, Venkataraman K. Amiodarone toxicity: II. Desethylamiodarone-induced phospholipidosis and ultrastructural changes during repeated administration in rats. Fundam Appl. Toxicol. 1991;16(1):103–9.
Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharm Rev. 1990;42:327–53.
Kodavanti UP, Lockard VG, Mehendale HM. In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats. J Biochem Toxicol. 1990;5:245–54.
Lullmann H, Lullmann-Rauch R. Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol. 1981;61(1):138–46.
Lullman-Rauch R, Nassberger L. Citalopram-induced generalized lipidosis in rats. Acta Pharmacol Toxicol. 1983;52(3):161–7.
Lullmann-Rauch R. Tilorone-induced lysosomal storage mimicking the features of mucopolysaccharidosis and of lipidosis in rat liver. Virchows Archiv B Cell Pathol. 1983;44(3):355–68.
Matsuzawa Y, Hostetler KY. Studies on drug induced lipidosis: subcellular localization of phopholipid and cholesterol in the liver of rats treated with chloroquine or 4,4-bis(diethylaminoethoxy) a,b-diethyldiphenylethane. J Lipid Res. 1980;21:202–14.
McCloud M, Beard T, Kacew S, Reasor M. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. Exp Mol Pathol. 1995;62:12–21.
Reasor MJ. A review of the biology and toxicologic implications of the induction of lysosmol lamellar bodies by drugs. Toxicol Appl Pharmacol. 1989;97:47–56.
Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med. 2001;226:825–30.
Sauers LJ, Wierda D, Walker ER, Reasor MJ. Morphological and functional changes in mouse splenic lymphocytes following in vivo and in vitro exposure to chlorphentermine. J Immunopharmacol. 1986;8(4):611–31.
Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005;83(2):282–92.
Shaikh NA, Downar E, Butany J. Amiodarone – an inhibitor of phospholipase activity: a comparative study of the inhibitory effect of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem 1987;76:163–72.
Tanaka H, Furusato M, Takasaki S, Watanabe M, Hattori Y. Morphological and biochemical alteration in the rat liver induced by maprotiline. Acta Pathol Jpn. 1975;25(4):413–37.
Ulrich RG, Kilgore KS, Sun EL, Cramer CT, Ginsburg LC. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol Methods. 1991;1(2):89–105.
Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol. 1996;314(1–2):203–14.
Westphal JF, Vetter D, Brogard JM. Hepatic side effects of antibiotics. J Antimicrob Chemother. 1994:33(3):387–401.
Whitehouse LW, Menzies A, Mueller R, Pontefract R. Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole. Toxicology. 1994;94(1–3):81–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morelli, J.K., Buehrle, M., Pognan, F. et al. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol 22, 15–27 (2006). https://doi.org/10.1007/s10565-006-0176-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10565-006-0176-z